STALICLA’s In-Licensing Agreement with Novartis

Goodwin Procter advised STALICLA SA on the deal.STALICLA SA announced its exclusive in-licensing agreement with Novartis to develop mavoglurant as a treatment for substance-use disorder, neurodevelopmental disorders,…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now